Signifor® LAR (Pasireotide Pamoate) - CAM 967HB

Background

FDA-Approved Indications: Signifor LAR is a long-acting somatostatin analog indicated for:

  1. Treatment of patients with acromegaly who have had an inadequate response to surgery or for whom surgery is not an option.
  2. Treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.

Policy (Criteria)

Acromegaly

Initial Authorization Criteria

Signifor LAR may be considered medically necessary when all of the following criteria are met:

1. Diagnosis of acromegaly

2. One of the following:

  • Inadequate response to pituitary surgery
  • Patient is not a candidate for surgery

3. Prescribed by or in consultation with an endocrinologist

Authorization Duration: 6 months

Reauthorization Criteria

Signifor LAR may be reauthorized when all of the following criteria are met:

1. Documentation of a positive clinical response to therapy examples includes one or more of the following:

  • Normalization or improvement of growth hormone (GH) levels
  • Normalization or improvement of age- and sex-adjusted insulin-like growth factor-1 (IGF-1) levels
  • Improvement in symptoms of acromegaly (e.g., headaches, excessive sweating, fatigue, soft tissue swelling)
  • Stabilization or reduction in tumor size when clinically appropriate

2. Continued prescribing by or in consultation with an endocrinologist

Authorization Duration: 12 months

Endogenous Cushing's Disease

Initial Authorization Criteria

Signifor LAR may be considered medically necessary when all of the following criteria are met:

1. Diagnosis of endogenous Cushing's disease

2. One of the following:

  • Pituitary surgery has not been curative
  • Patient is not a candidate for pituitary surgery

3. Prescribed by or in consultation with an endocrinologist

Authorization Duration: 6 months

Reauthorization Criteria

Signifor LAR may be reauthorized when all of the following criteria are met:

1. Documentation of a positive clinical response to therapy examples include one or more of the following:

  • Clinically meaningful reduction in 24-hour urinary free cortisol (UFC) levels
  • Normalization or improvement in cortisol levels
  • Improvement in Cushing's disease signs and symptoms
  • Improvement in blood pressure, glucose control, weight, or other metabolic abnormalities associated with hypercortisolism
  • Improvement in quality of life and functional status

2. Continued prescribing by or in consultation with an endocrinologist

Authorization Duration: 12 months

References

  1. Signifor® LAR (pasireotide pamoate) Prescribing Information. Recordati Rare Diseases Inc. Current prescribing information.
  2. Melmed S, Bronstein MD, Chanson P, et al. A Randomized Phase III Trial of Pasireotide LAR in Acromegaly. Journal of Clinical Endocrinology & Metabolism. 2015;100(2):791-799.
  3. Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide Versus Continued Treatment With First-Generation Somatostatin Analogs in Acromegaly. Lancet Diabetes & Endocrinology. 2014;2(11):875-884.
  4. Lacroix A, Gu F, Gallardo W, et al. Pasireotide Treatment Significantly Reduces Cortisol Levels in Patients With Cushing's Disease. Pituitary. 2016;19(4):336-346.
  5. Fleseriu M, Petersenn S, Biller BMK, et al. Long-Term Efficacy and Safety of Pasireotide in Cushing's Disease. Endocrine. 2019;64(1):67-80.
  6. Endocrine Society Clinical Practice Guideline: Acromegaly. Current version.
  7. Endocrine Society Clinical Practice Guideline: Treatment of Cushing's Syndrome. Current version.
  8. GeneReviews®. Acromegaly and Cushing Disease clinical overviews.

Coding Section

Code

Number

Description

HCPCS

J2502

Injection, pasireotide long acting, 1 mg

 

J3490

Unclassified drugs

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each Policy. They may not be all-inclusive.

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

"Current Procedural Terminology © American Medical Association. All Rights Reserved" 

History From 2026 Forward

10/01/2026

New Policy

Complementary Content
${loading}